Molecular basis for agonism in the BB3 receptor: An epitope located on the interface of transmembrane-III, -VI, and -VII

Journal of Pharmacology and Experimental Therapeutics

Volumn 333, Issue 1, 2010, Pages 51-59

  Gbahou, F ^a,b   Holst, B ^a   Schwartz, T W ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BOMBESIN RECEPTOR; BOMBESIN RECEPTOR SUBTYPE 3; BOMBESIN RECEPTOR SUBTYPE 3 AGONIST; EPITOPE; METAL ION; PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HUMAN; LIGAND BINDING; LOSS OF FUNCTION MUTATION; MUTAGENESIS; MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BINDING SITES; BOMBESIN; CELL LINE; EPITOPES; HUMANS; LIGANDS; MODELS, MOLECULAR; MUTATION; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; RECEPTORS, BOMBESIN; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949764193     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.162131     Document Type: Article

References (36)

1. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, et al. (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272:22330-22339.
2. Boyle RG, Humphries J, Mitchell T, Showell GA, Apaya R, Iijima H, Shimada H, Arai T, Ueno H, Usui Y, et al. (2005) The design of a new potent and selective ligand for the orphan bombesin receptor subtype 3 (BRS3). J Pept Sci 11:136-141.
3. Carlton DL, Collin-Smith LJ, Daniels AJ, Deaton DN, Goetz AS, Laudeman CP, Littleton TR, Musso DL, Morgan RJ, Szewczyk JR, et al. (2008) Discovery of small molecule agonists for the bombesin receptor subtype 3 (BRS-3) based on an omeprazole lead. Bioorg Med Chem Lett 18:5451-5455.
4. Del Carmine R, Molinari P, Sbraccia M, Ambrosio C, and Costa T (2004) "Induced-fit" mechanism for catecholamine binding to the beta2-adrenergic receptor. Mol Pharmacol 66:356-363.
5. Elling CE, Frimurer TM, Gerlach LO, Jorgensen R, Holst B, and Schwartz TW (2006) Metal ion site engineering indicates a global toggle switch model for seven-transmembrane receptor activation. J Biol Chem 281:17337- 17346.
6. Elling CE, Thirstrup K, Holst B, and Schwartz TW (1999) Conversion of agonist site to metal-ion chelator site in the beta(2)-adrenergic receptor. Proc Natl Acad Sci U S A 96:12322-12327.
7. Fathi Z, Corjay MH, Shapira H, Wada E, Benya R, Jensen R, Viallet J, Sausville EA, and Battey JF (1993) BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J Biol Chem 268:5979-5984.
8. Fong TM, Yu H, Huang RR, and Strader CD (1992) The extracellular domain of the neurokinin-1 receptor is required for high-affinity binding of peptides. Biochemistry 31:11806-11811.
9. Gonzalez N, Hocart SJ, Portal-Nuñez S, Mantey SA, Nakagawa T, Zudaire E, Coy DH, and Jensen RT (2008) Molecular basis for agonist selectivity and activation of the orphan bombesin receptor subtype 3 receptor. J Pharmacol Exp Ther 324:463-474.
10. Hjorth SA, Schambye HT, Greenlee WJ, and Schwartz TW (1994) Identification of peptide binding residues in the extracellular domains of the AT1 receptor. J Biol Chem 269:30953-30959.
11. Holst B and Schwartz TW (2003) Molecular mechanism of agonism and inverse agonism in the melanocortin receptors: Zn(2+) as a structural and functional probe. Ann N Y Acad Sci 994:1-11.
12. Holst B and Schwartz TW (2006) Ghrelin receptor mutations - too little height and too much hunger. J Clin Invest 116:637-641.
13. Holst B, Elling CE, and Schwartz TW (2000) Partial agonism through a zinc-Ion switch constructed between transmembrane domains III and VII in the tachykinin NK(1) receptor. Mol Pharmacol 58:263-270.
14. Holst B, Frimurer TM, Mokrosinski J, Halkjaer T, Cullberg KB, Underwood CR, and Schwartz TW (2009) Overlapping binding site for the endogenous agonist, small-molecule agonists, and ago-allosteric modulators on the ghrelin receptor. Mol Pharmacol 75:44-59.
15. Holst B, Holliday ND, Bach A, Elling CE, Cox HM, and Schwartz TW (2004) Common structural basis for constitutive activity of the ghrelin receptor family. J Biol Chem 279:53806-53817.
16. Holst B, Lang M, Brandt E, Bach A, Howard A, Frimurer TM, Beck-Sickinger A, and Schwartz TW (2006) Ghrelin receptor inverse agonists: identification of an active peptide core and its interaction epitopes on the receptor. Mol Pharmacol 70:936-946.
17. Holst B, Mokrosinski J, Lang M, Brandt E, Nygaard R, Frimurer TM, Beck-Sickinger AG, and Schwartz TW (2007) Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem 282:15799-15811.
18. Holst B, Zoffmann S, Elling CE, Hjorth SA, and Schwartz TW (1998) Steric hindrance mutagenesis versus alanine scan in mapping of ligand binding sites in the tachykinin NK1 receptor. Mol Pharmacol 53:166-175.
19. Horton RM, Hunt HD, Ho SN, Pullen JK, and Pease LR (1989) Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77:61-68.
20. Jensen PC, Nygaard R, Thiele S, Elder A, Zhu G, Kolbeck R, Ghosh S, Schwartz TW, and Rosenkilde MM (2007) Molecular interaction of a potent nonpeptide agonist with the chemokine receptor Ccr8. Mol Pharmacol 72:327-340.
21. Jensen RT, Battey JF, Spindel ER, and Benya RV (2008) International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev 60:1-42.
22. Liu C, Wu J, Zhu J, Kuei C, Yu J, Shelton J, Sutton SW, Li X, Yun SJ, Mirzadegan T, et al. (2009) Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81. J Biol Chem 284:2811-2822.
23. Maekawa F, Quah HM, Tanaka K, and Ohki-Hamazaki H (2004) Leptin resistance and enhancement of feeding facilitation by melanin-concentrating hormone in mice lacking bombesin receptor subtype-3. Diabetes 53:570-576.
24. Mantey SA, Coy DH, Entsuah LK, and Jensen RT (2004) Development of bombesin analogs with conformationally restricted amino acid substitutions with enhanced selectivity for the orphan receptor human bombesin receptor subtype 3. J Pharmacol Exp Ther 310:1161-1170.
25. Mantey SA, Coy DH, Pradhan TK, Igarashi H, Rizo IM, Shen L, Hou W, Hocart SJ, and Jensen RT (2001) Rational design of a peptide agonist that interacts selectively with the orphan receptor, bombesin receptor subtype 3. J Biol Chem 276:9219-9229.
26. Mantey SA, Gonzalez N, Schumann M, Pradhan TK, Shen L, Coy DH, and Jensen RT (2006) Identification of bombesin receptor subtype-specific ligands: effect of N-methyl scanning, truncation, substitution, and evaluation of putative reported selective ligands. J Pharmacol Exp Ther 319:980-989.
27. Nakamichi Y, Wada E, Aoki K, Ohara-Imaizumi M, Kikuta T, Nishiwaki C, Matsushima S, Watanabe T, Wada K, and Nagamatsu S (2004) Functions of pancreatic beta cells and adipocytes in bombesin receptor subtype-3-deficient mice. Biochem Biophys Res Commun 318:698-703.
28. Nygaard R, Frimurer TM, Holst B, Rosenkilde MM, and Schwartz TW (2009) Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol Sci 30:249-259.
29. Ohki-Hamazaki H, Wada E, Matsui K, and Wada K (1997a) Cloning and expression of the neuromedin B receptor and the third subtype of bombesin receptor genes in the mouse. Brain Res 762:165-172.
30. Ohki-Hamazaki H, Watase K, Yamamoto K, Ogura H, Yamano M, Yamada K, Maeno H, Imaki J, Kikuyama S, et al. (1997b) Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity. Nature 390:165-169.
31. Pantel J, Legendre M, Cabrol S, Hilal L, Hajaji Y, Morisset S, Nivot S, Vie-Luton MP, Grouselle D, de Kerdanet M, et al. (2006) Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J Clin Invest 116:760-768.
32. Porcher C, Juhem A, Peinnequin A, and Bonaz B (2005) Bombesin receptor subtype-3 is expressed by the enteric nervous system and by interstitial cells of Cajal in the rat gastrointestinal tract. Cell Tissue Res 320:21-31.
33. Ryan RR, Weber HC, Hou W, Sainz E, Mantey SA, Battey JF, Coy DH, and Jensen RT (1998) Ability of various bombesin receptor agonists and antagonists to alter intracellular signaling of the human orphan receptor BRS-3. J Biol Chem 273:13613-13624.
34. Sano H, Feighner SD, Hreniuk DL, Iwaasa H, Sailer AW, Pan J, Reitman ML, Kanatani A, Howard AD, and Tan CP (2004) Characterization of the bombesin-like peptide receptor family in primates. Genomics 84:139-146.
35. Schwartz TW, Frimurer TM, Holst B, Rosenkilde MM, and Elling CE (2006) Molecular mechanism of 7TM receptor activation - a global toggle switch model. Annu Rev Pharmacol Toxicol 46:481-519.
36. Storjohann L, Holst B, and Schwartz TW (2008) Molecular mechanism of Zn2+ agonism in the extracellular domain of GPR39. FEBS Lett 582:2583-2588.